Fingolimod: clinical use
Evidence-based neurology checklist on fingolimod: clinical use: Mode of action Fingolimod is derived from the fungus Isaria sinclairii It binds sphingosine-1-phosphate (S1P) receptors on lymphocytes It also inhibits lymphocyte migration out of lymphatic tissue Serum and CSF neurofilament light…
Mode of action
- Fingolimod is derived from the fungus Isaria sinclairii
- It binds sphingosine-1-phosphate (S1P) receptors on lymphocytes
- It also inhibits lymphocyte migration out of lymphatic tissue
- Serum and CSF neurofilament light chain (NFL) are markers of treatment response
Indications
Dose
Contraindications
Contraindications: others
Fingolimod and pregnancy
Acronym
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011; 25:673-689.
- Kappos L, Radue EW, O'Connor P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. NEJM 2010; 362:387-401.
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing−remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13:545–556.
- Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29:565-575.
- And 7 more. Subscribe to see the full list
